INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 142 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8,322,464 | -10.8% | 131,435 | -23.7% | 0.33% | -8.2% |
| Q1 2023 | $9,333,890 | +2.3% | 172,371 | 0.0% | 0.36% | +2.9% |
| Q4 2022 | $9,121,873 | +13.7% | 172,371 | 0.0% | 0.34% | +5.2% |
| Q3 2022 | $8,020,000 | -42.3% | 172,371 | -29.2% | 0.33% | -39.9% |
| Q2 2022 | $13,895,000 | -21.9% | 243,437 | -16.3% | 0.55% | -12.6% |
| Q1 2022 | $17,802,000 | +43.8% | 290,936 | +23.0% | 0.62% | +57.0% |
| Q4 2021 | $12,376,000 | +2.3% | 236,447 | -27.1% | 0.40% | +2.3% |
| Q3 2021 | $12,094,000 | +46.1% | 324,401 | +60.0% | 0.39% | +44.6% |
| Q2 2021 | $8,276,000 | +4.9% | 202,756 | -12.8% | 0.27% | -0.7% |
| Q1 2021 | $7,888,000 | -32.3% | 232,476 | -36.5% | 0.27% | -33.7% |
| Q4 2020 | $11,644,000 | +381.6% | 366,176 | +288.6% | 0.41% | +349.5% |
| Q3 2020 | $2,418,000 | -0.0% | 94,238 | 0.0% | 0.09% | -1.1% |
| Q2 2020 | $2,419,000 | +67.1% | 94,238 | 0.0% | 0.09% | +41.5% |
| Q1 2020 | $1,448,000 | -55.2% | 94,238 | 0.0% | 0.06% | -46.7% |
| Q4 2019 | $3,233,000 | +1469.4% | 94,238 | +242.1% | 0.12% | +1255.6% |
| Q3 2019 | $206,000 | -71.2% | 27,548 | -50.0% | 0.01% | -69.0% |
| Q2 2019 | $715,000 | -46.7% | 55,096 | -50.0% | 0.03% | -47.3% |
| Q1 2019 | $1,342,000 | +6.9% | 110,193 | 0.0% | 0.06% | +1.9% |
| Q4 2018 | $1,255,000 | +66.0% | 110,193 | +216.2% | 0.05% | +100.0% |
| Q3 2018 | $756,000 | -89.6% | 34,850 | -81.4% | 0.03% | -90.9% |
| Q2 2016 | $7,290,000 | +39.6% | 187,800 | 0.0% | 0.30% | +34.2% |
| Q1 2016 | $5,221,000 | -48.3% | 187,800 | 0.0% | 0.22% | -39.3% |
| Q4 2015 | $10,102,000 | +68.2% | 187,800 | +25.2% | 0.37% | +69.4% |
| Q3 2015 | $6,006,000 | -17.2% | 150,000 | -34.0% | 0.22% | -17.9% |
| Q2 2015 | $7,258,000 | +102.6% | 227,164 | +51.4% | 0.26% | +85.2% |
| Q1 2015 | $3,582,000 | – | 150,000 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |